Drug Trial Radar · NCT06195540
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,424
Planned (sponsor's estimate)
Start
Jul 19, 2024
Primary completion
Nov 19, 2028
Study completion Nov 19, 2028
Sponsor
- Lead sponsor
- University Hospital, AngersGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \<7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms. The aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.
Conditions
- Venous Thromboembolism
- Deep Vein Thrombosis
- Pulmonary Embolism
- Lower Limb Trauma
- Thromboprophylaxis
- Immobilisation
Interventions
Rivaroxaban 10 MGDrug
Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb. Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment). Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Low Heparin Molecular WeightDrug
Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations. Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of symptomatic venous thromboembolic events (45 days non-inferiority)Time frame: 45 days
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Agen-Nerac Hospital, Emergency Department
Agen, France · Active not recruiting
Angers University Hospital, Emergency department
Angers, France · Recruiting
Argenteuil hospital, Emergency department
Argenteuil, France · Recruiting
Arpajon Hospital, Emergency Department
Arpajon, France · Withdrawn
Caen University hospital, Emergency department
Caen, France · Withdrawn
Tours University Hospital, Emergency department
Chambray-lès-Tours, France · Withdrawn
Cholet Hospital, Emergency department
Cholet, France · Recruiting
Clermont-Ferrand University Hospital, Emergency department
Clermont-Ferrand, France · Recruiting
Simone Veil Hospital, Emergency Department
Eaubonne, France · Recruiting
Eure-Seine Hospital, Emergency Departement
Évreux, France · Active not recruiting
Grenoble University Hospital, Emergency Department
Grenoble, France · Recruiting
La Roche sur Yon Hospital
La Roche-sur-Yon, France · Not yet recruiting
La Rochelle Hospital, Adult emergency departement
La Rochelle, France · Recruiting
Le Mans Hospital, Emergency department
Le Mans, France · Recruiting
Limoges University hospital, Emergency department
Limoges, France · Recruiting
Edouard Herriot University Hospital, Emergency Department
Lyon, France · Recruiting
Marseille University Hospital, Emergency department
Marseille, France · Recruiting
Melun Hospital, Emergency Department
Melun, France · Recruiting
Montpellier University Hospital, emergency department
Montpellier, France · Recruiting
Nancy University Hospital, Emergency department
Nancy, France · Not yet recruiting
Nantes University Hospital, Emergency department
Nantes, France · Recruiting
Nice University Hospital, Emergency department
Nice, France · Withdrawn
Niort Hospital, Emergency Department
Niort, France · Recruiting
Lariboisière hospital, emergency department
Paris, France · Not yet recruiting
Saint-Antoine Hospital, Emergency department
Paris, France · Recruiting
La Pitié-Salpétrière Hospital, Emergency Department
Paris, France · Not yet recruiting
Cochin Hospital, Emergency department
Paris, France · Recruiting
St-Joseph Hospital, Emergency Department
Paris, France · Recruiting
HEGP, Emergency Department
Paris, France · Recruiting
Bichat Hospital, Adult Emergency department
Paris, France · Recruiting
South Lyon University Hospital, Emergency department
Pierre-Bénite, France · Recruiting
Poitiers University Hospital, Emergency department
Poitiers, France · Recruiting
Rennes University Hospital, Emergency department
Rennes, France · Recruiting
Rouen University Hospital, Emergency Department
Rouen, France · Not yet recruiting
Strasbourg University Hospital, Emergency Department
Strasbourg, France · Recruiting
Toulouse University Hospital, Emergency Department
Toulouse, France · Recruiting
Vannes Hospital, Emergency Department
Vannes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.